Sana Biotechnology (SANA)
(Delayed Data from NSDQ)
$8.60 USD
+0.69 (8.72%)
Updated May 14, 2024 04:00 PM ET
4-Sell of 5 4
D Value C Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for Sana Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 209 | 430 | 551 | 378 | 139 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 14 | 7 | 6 | 5 |
Total Current Assets | 214 | 444 | 558 | 384 | 144 |
Net Property & Equipment | 71 | 67 | 65 | 47 | 28 |
Investments & Advances | 0 | 10 | 196 | 34 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 200 | 200 | 200 | 200 | 200 |
Deposits & Other Assets | 6 | 9 | 14 | 2 | 2 |
Total Assets | 565 | 823 | 1,129 | 730 | 415 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 3 | 2 | 2 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 47 | 41 | 31 | 25 | 18 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 55 | 56 | 0 | 0 |
Total Current Liabilities | 64 | 112 | 99 | 31 | 19 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 122 | 116 | 200 | 199 | 75 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 853 | 0 |
Total Liabilities | 278 | 323 | 401 | 1,151 | 140 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 417 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,626 | 1,558 | 1,515 | 8 | 2 |
Retained Earnings | -1,338 | -1,055 | -785 | -429 | -144 |
Other Equity | 0 | -4 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 288 | 499 | 729 | -421 | 275 |
Total Liabilities & Shareholder's Equity | 565 | 823 | 1,129 | 730 | 415 |
Total Common Equity | 288 | 499 | 729 | -421 | -143 |
Shares Outstanding | 197.10 | 190.70 | 188.80 | NA | NA |
Book Value Per Share | 1.46 | 2.62 | 3.86 | 0.00 | 0.00 |
Fiscal Year End for Sana Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 315 | 209 | 272 | 332 | 355 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 4 | 7 | 7 | 15 |
Total Current Assets | 321 | 214 | 280 | 339 | 370 |
Net Property & Equipment | 82 | 71 | 68 | 63 | 64 |
Investments & Advances | 0 | 0 | 0 | 0 | 6 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 200 | 200 | 200 | 200 | 200 |
Deposits & Other Assets | 7 | 6 | 6 | 11 | 9 |
Total Assets | 681 | 565 | 631 | 707 | 747 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 4 | 10 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 34 | 47 | 43 | 38 | 30 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 58 | 57 |
Total Current Liabilities | 53 | 64 | 67 | 112 | 103 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 160 | 116 | 140 | 114 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 306 | 278 | 266 | 352 | 319 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,821 | 1,626 | 1,616 | 1,607 | 1,567 |
Retained Earnings | -1,446 | -1,338 | -1,250 | -1,251 | -1,137 |
Other Equity | 0 | 0 | 0 | -1 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 375 | 288 | 366 | 355 | 428 |
Total Liabilities & Shareholder's Equity | 681 | 565 | 631 | 707 | 747 |
Total Common Equity | 375 | 288 | 366 | 355 | 428 |
Shares Outstanding | 220.40 | 197.10 | 196.90 | 196.90 | 191.40 |
Book Value Per Share | 1.70 | 1.46 | 1.86 | 1.80 | 2.24 |